Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
11 hedge funds and large institutions have $107K invested in Timber Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 9 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
31% less funds holding
Funds holding: 16 → 11 (-5)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
86% less capital invested
Capital invested by funds: $752K → $107K (-$645K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$31.6K |
| 2 |
Bank of New York Mellon
New York
|
+$18.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.27K |
| 5 |
Morgan Stanley
New York
|
+$19 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$176K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$39K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$38K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$15K |
| 5 |
State Street
Boston,
Massachusetts
|
-$13K |
TMBR Hedge Fund Activity: Q4 2022 in Review
11 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q4 2022, worth a combined $107K — down 86% from $752K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TMBR and 4 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $31.6K. The largest seller was Vanguard Group, cutting an estimated $176K.
- 11 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q4 2022, down from 16 in Q3 2022.
- Funds reported $107K of Timber Pharmaceuticals, Inc. stock for Q4 2022, down 86% quarter-over-quarter.
- 4 funds opened new Timber Pharmaceuticals, Inc. positions in Q4 2022 and 9 closed out, a net change of -5 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q4 2022 was Sabby Management, an estimated $31.6K added.
- The largest Timber Pharmaceuticals, Inc. seller in Q4 2022 was Vanguard Group, an estimated $176K sold.
Based on aggregated 13F filings for Q4 2022.